Simultaneous Assessment of Clearance, Metabolism, Induction, and Drug-Drug Interaction Potential Using a Long-Term In Vitro Liver Model for a Novel Hepatitis B Virus Inhibitor

Long-term in vitro liver models are now widely explored for human hepatic metabolic clearance prediction, enzyme phenotyping, cross-species metabolism, comparison of low clearance drugs, and induction studies. Here, we present studies using a long-term liver model, which show how metabolism and active transport, drug-drug interactions, and enzyme induction in healthy and diseased states, such as hepatitis B virus (HBV) infection, may be assessed in a single test system to enable effective data integration for physiologically based pharmacokinetic (PBPK) modeling. The approach is exemplified in the case of (3S)-4-[[(4R)-4-(2-Chloro-4-fluorophenyl)-5-methoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidin-6-yl]methyl]morpholine-3-carboxylic acid RO6889678, a novel inhibitor of HBV with a complex absorption, distribution, metabolism, and excretion (ADME) profile. RO6889678 showed an intracellular enrichment of 78-fold in hepatocytes, with an apparent intrinsic clearance of 5.2 µl/min per mg protein and uptake and biliary clearances of 2.6 and 1.6 µl/min per mg protein, respectively. When apparent intrinsic clearance was incorporated into a PBPK model, the simulated oral human profiles were in good agreement with observed data at low doses but were underestimated at high doses due to unexpected overproportional increases in exposure with dose. In addition, the induction potential of RO6889678 on cytochrome P450 (P450) enzymes and transporters at steady state was assessed and cotreatment with ritonavir revealed a complex drug-drug interaction with concurrent P450 inhibition and moderate UDP-glucuronosyltransferase induction. Furthermore, we report on the first evaluation of in vitro pharmacokinetics studies using HBV-infected HepatoPac cocultures. Thus, long-term liver models have great potential as translational research tools exploring pharmacokinetics of novel drugs in vitro in health and disease.

[1]  Vyas Ramanan,et al.  Modeling host interactions with hepatitis B virus using primary and induced pluripotent stem cell-derived hepatocellular systems , 2014, Proceedings of the National Academy of Sciences.

[2]  Niresh Hariparsad,et al.  Evaluation of the Interplay between Uptake Transport and CYP3A4 Induction in Micropatterned Cocultured Hepatocytes , 2016, Drug Metabolism and Disposition.

[3]  G. Camenisch,et al.  Novel In Vitro-In Vivo Extrapolation (IVIVE) Method to Predict Hepatic Organ Clearance in Rat , 2011, Pharmaceutical Research.

[4]  G. Camenisch,et al.  Drug Disposition Classification Systems in Discovery and Development: A Comparative Review of the BDDCS, ECCS and ECCCS Concepts , 2016, Pharmaceutical Research.

[5]  Jialin Mao,et al.  Prediction of CYP3A-Mediated Drug-Drug Interactions Using Human Hepatocytes Suspended in Human Plasma , 2011, Drug Metabolism and Disposition.

[6]  Hugh A Barton,et al.  Model-based approaches to predict drug–drug interactions associated with hepatic uptake transporters: preclinical, clinical and beyond , 2013, Expert opinion on drug metabolism & toxicology.

[7]  Ken Grime,et al.  Determination of Human Hepatocyte Intrinsic Clearance for Slowly Metabolized Compounds: Comparison of a Primary Hepatocyte/Stromal Cell Co-culture with Plated Primary Hepatocytes and HepaRG , 2016, Drug Metabolism and Disposition.

[8]  Osamu Okazaki,et al.  Predictability of Idiosyncratic Drug Toxicity Risk for Carboxylic Acid-Containing Drugs Based on the Chemical Stability of Acyl Glucuronide , 2010, Drug Metabolism and Disposition.

[9]  B. Ring,et al.  Low-Turnover Drug Molecules: A Current Challenge for Drug Metabolism Scientists , 2015, Drug Metabolism and Disposition.

[10]  Tudor I. Oprea,et al.  BDDCS Applied to Over 900 Drugs , 2011, The AAPS Journal.

[11]  T. Muir,et al.  Long-term hepatitis B infection in a scalable hepatic co-culture system , 2017, Nature Communications.

[12]  Applying Stable Isotope Labeled Amino Acids in Micropatterned Hepatocyte Coculture to Directly Determine the Degradation Rate Constant for CYP3A4 , 2017, Drug Metabolism and Disposition.

[13]  Robert J Riley,et al.  EVALUATION OF FRESH AND CRYOPRESERVED HEPATOCYTES AS IN VITRO DRUG METABOLISM TOOLS FOR THE PREDICTION OF METABOLIC CLEARANCE , 2004, Drug Metabolism and Disposition.

[14]  N. Hariparsad,et al.  Quantitative Prediction of CYP3A4 Induction: Impact of Measured, Free, and Intracellular Perpetrator Concentrations from Human Hepatocyte Induction Studies on Drug-Drug Interaction Predictions , 2017, Drug Metabolism and Disposition.

[15]  M Rowland,et al.  Physiologic pharmacokinetic models and interanimal species scaling. , 1985, Pharmacology & therapeutics.

[16]  Hugh A. Barton,et al.  Mechanistic Pharmacokinetic Modeling for the Prediction of Transporter-Mediated Disposition in Humans from Sandwich Culture Human Hepatocyte Data , 2012, Drug Metabolism and Disposition.

[17]  D. Tweedie,et al.  Determination of a Degradation Constant for CYP3A4 by Direct Suppression of mRNA in a Novel Human Hepatocyte Model, HepatoPac , 2015, Drug Metabolism and Disposition.

[18]  Jennifer Q. Dong,et al.  Glucuronidation and Covalent Protein Binding of Benoxaprofen and Flunoxaprofen in Sandwich-Cultured Rat and Human Hepatocytes , 2009, Drug Metabolism and Disposition.

[19]  R. Riley,et al.  EVALUATION OF TIME-DEPENDENT CYTOCHROME P450 INHIBITION USING CULTURED HUMAN HEPATOCYTES , 2006, Drug Metabolism and Disposition.

[20]  Dvora Witt-Kehati,et al.  Advances and Challenges in Studying Hepatitis B Virus In Vitro , 2016, Viruses.

[21]  M A Nowak,et al.  Viral dynamics in hepatitis B virus infection. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Malcolm Rowland,et al.  Human clearance prediction: shifting the paradigm , 2009, Expert opinion on drug metabolism & toxicology.

[23]  Christine Lin,et al.  Prediction of Drug Clearance and Drug-Drug Interactions in Microscale Cultures of Human Hepatocytes , 2016, Drug Metabolism and Disposition.

[24]  Niresh Hariparsad,et al.  Application of Micropatterned Cocultured Hepatocytes to Evaluate the Inductive Potential and Degradation Rate of Major Xenobiotic Metabolizing Enzymes , 2016, Drug Metabolism and Disposition.

[25]  A. D. Rodrigues,et al.  Reliable Rate Measurements for Active and Passive Hepatic Uptake Using Plated Human Hepatocytes , 2017, The AAPS Journal.

[26]  Daniel Bischoff,et al.  Upcyte Human Hepatocytes: a Potent In Vitro Tool for the Prediction of Hepatic Clearance of Metabolically Stable Compounds , 2016, Drug Metabolism and Disposition.

[27]  Loretta M Cox,et al.  Application of a Micropatterned Cocultured Hepatocyte System To Predict Preclinical and Human-Specific Drug Metabolism , 2016, Drug Metabolism and Disposition.

[28]  G. von Heijne,et al.  Tissue-based map of the human proteome , 2015, Science.

[29]  Mitchell E Taub,et al.  Bridging In Vitro and In Vivo Metabolism and Transport of Faldaprevir in Human Using a Novel Cocultured Human Hepatocyte System, HepatoPac , 2014, Drug Metabolism and Disposition.

[30]  Aleksandra Galetin,et al.  Rationalizing underprediction of drug clearance from enzyme and transporter kinetic data: from in vitro tools to mechanistic modeling. , 2014, Methods in molecular biology.

[31]  Heather E Fleming,et al.  Micropatterned coculture of primary human hepatocytes and supportive cells for the study of hepatotropic pathogens , 2015, Nature Protocols.

[32]  Malcolm Rowland,et al.  Mechanistic Approaches to Volume of Distribution Predictions: Understanding the Processes , 2007, Pharmaceutical Research.

[33]  O. J. Trask,et al.  A micropatterned hepatocyte coculture model for assessment of liver toxicity using high-content imaging analysis. , 2014, Assay and drug development technologies.

[34]  N Parrott,et al.  Physiologically based pharmacokinetic modeling in drug discovery and development: A pharmaceutical industry perspective , 2015, Clinical pharmacology and therapeutics.

[35]  Susanne Winiwarter,et al.  Use of HμREL Human Coculture System for Prediction of Intrinsic Clearance and Metabolite Formation for Slowly Metabolized Compounds. , 2016, Molecular pharmaceutics.

[36]  P. Bachellier,et al.  Prediction of fraction metabolized via CYP3A in humans utilizing cryopreserved human hepatocytes from a set of 12 single donors , 2014, Xenobiotica; the fate of foreign compounds in biological systems.

[37]  J. Kao,et al.  Natural history of acute and chronic hepatitis B: The role of HBV genotypes and mutants. , 2017, Best practice & research. Clinical gastroenterology.

[38]  Hongbin Yu,et al.  Special Section on Prediction of Human Pharmacokinetic Parameters from In Vitro Systems Meeting the Challenge of Predicting Hepatic Clearance of Compounds Slowly Metabolized by Cytochrome P450 Using a Novel Hepatocyte Model, HepatoPac , 2013 .

[39]  Neil Parrott,et al.  Applications of physiologically based absorption models in drug discovery and development. , 2008, Molecular pharmaceutics.

[40]  Thierry Lavé,et al.  Metabolic Profiling of Human Long-Term Liver Models and Hepatic Clearance Predictions from In Vitro Data Using Nonlinear Mixed-Effects Modeling , 2017, The AAPS Journal.

[41]  S. Steyn,et al.  Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS) , 2015, Pharmaceutical Research.

[42]  L. Tremaine,et al.  Hepatobiliary Clearance Prediction: Species Scaling From Monkey, Dog, and Rat, and In Vitro-In Vivo Extrapolation of Sandwich-Cultured Human Hepatocytes Using 17 Drugs. , 2017, Journal of pharmaceutical sciences.

[43]  M. T. Donato,et al.  Human hepatocytes in primary culture: the choice to investigate drug metabolism in man. , 2004, Current drug metabolism.